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Abstract
Gliomas aberrantly express programmed cell death ligand-1 (PD-L1), which has a pivotal role in immunoevasion. The
splicing isoform of FKBP5, termed FKBP51s, is a PD-L1 foldase, assisting the immune checkpoint molecule in
maturation and expression on the plasma membrane. The concept that PD-L1 supports tumor-intrinsic properties is
increasingly emerging. The aim of the present work was to confirm the pro-tumoral effect of PD-L1 on human glioma
cell survival, stemness capacity and resistance, and to address the issue of whether, by targeting its foldase either
chemically or by silencing, the aggressive tumor features could be attenuated. PD-L1-depleted glioma cells have a
reduced threshold for apoptosis, while PD-L1 forced expression increases resistance. Similar results were obtained with
FKBP51s modulation. The ability of PD-L1 to counteract cell death was hampered by FKBP51s silencing. PD-L1
expression was particularly high in glioma cells with a cancer-stem-cell profile. Moreover, PD-L1 sustained the spheroid
formation capability of glioma cells. Targeting of FKBP51s by small-interfering RNA (siRNA) or the specific inhibitor
SAFit2, reduced the number of formed spheroids, along with PD-L1 expression. Finally, in an orthotopic mouse model
of glioblastoma, daily treatment with SAFit2 significantly reduced tumor PD-L1 expression, and tumor growth. In
treated mice, caspase-3 activation and reduced vimentin expression were observed in excised tumors. In conclusion,
targeting of FKBP51s hampers PD-L1 and its pro-tumoral properties, thereby affecting the self-renewal and growth
capacities of glioblastoma cells in vitro and in vivo.
Introduction
Glioblastoma multiforme (GBM) is the most common,
but also the most dangerous and aggressive form of
primary brain cancer, for which no contemporary treat-
ments are curative. Gliomas, indeed, express several co-
inhibitory molecules that negatively regulate immune
system functions1–4, among which programmed cell death
ligand-1 (PD-L1) is one of the most represented and
studied3,4. The interaction of PD-L1 with its counter-
receptor programmed cell death-1 (PD-1) expressed by
activated T lymphocytes, inhibits T-cell activation and
proliferation, thus contributing to cancer immune eva-
sion5. So far, anti-PD-1 treatment has shown a therapeutic
efficacy limited to selected subsets of glioma patients6.
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Several studies are in progress, especially exploring the
combination of anti-PD-1 antibodies with chemotherapies
or targeted therapies6. It is worth noting that PD-L1 not
only binds to PD-1 but also competes with CD28-to-
CD80 binding7, suggesting that a PD-1 blockade may
sometimes be insufficient to prevent signals emanating
from PD-L1 receptors.
Recent studies show that, in addition to its immuno-
modulatory function, PD-L1 conveys a survival signal to
the cancer cell and sustains tumor aggressiveness6.
Azuma et al.8 found that PD-L1, upon ligand stimulation,
acts as a receptor that transduces pro-survival signals that
enhance the threshold for apoptosis induced by both
immune effectors and proapoptotic drugs. Zheng et al.9
found that PD-L1 sustains the self-renewal capability of
malignant melanoma-initiating cells. Most recently, Qiu
et al.10 demonstrated that PD-L1 binds to Ras and acti-
vates the Ras/Erk pathway. Via this mechanism, PD-L1
promotes the epithelial-to-mesenchymal transition
(EMT) and GBM cell migration.
Akt supports aberrant PD-L1 expression in glioma cells,
through a translational mechanism favouring the assem-
bly of a polyribosome complex that allows better entrance
of the PD-L1 transcript into polysomes11. PD-L1 glyco-
sylation is an essential element influencing protein stabi-
lity12. Most recently, in glioma, the splicing isoform of the
FK506-binding protein-51 (FKBP51s)13 was found to
serve as a PD-L1 co-chaperone, assisting in protein gly-
cosylation14. PD-L1 post-translational modifications have
been thoroughly reviewed by Hsu et al.15. According to
Jiang et al.16 and the Oncomine database (www.oncomine.
org), FKBP51 is among the top 10% of the most highly
expressed genes in GBM. The FKBP51 protein structure
includes a C-terminal TPR three-tandem-repeat domain
responsible for protein-protein interaction, and two N-
terminal FK domains, of which the one with most N
terminals exhibits peptidyl-prolyl cis-trans isomerase
(PPIase) activity17,18. FKBP51s is generated by alternative
splicing of FKBP5 pre-mRNA13, which causes a frameshift
with a premature stop codon, leading to a distinct C-
terminus, compared to the canonical isoform. FKBP51s
retains the PPIase activity but loses the TPR domain. An
IHC study on 29 GBM specimens showed that FKBP51s is
broadly expressed in this tumor, albeit with different
proportion/intensity scores, with nuclear and/or cyto-
plasmic localization14. Biochemical evaluation of glioma
cell lines showed that naive PD-L1 is complexed with
FKBP51s in the endoplasmic reticulum, whereas the gly-
cosylated form was detected in the Golgi apparatus14.
FKBP51s knockdown severely reduced the level of gly-
cosylated PD-L1, whether constitutively expressed or
induced by ionizing radiation14. The essential role of the
PPIase activity in PD-L1 protein maturation was con-
firmed by use of a selective inhibitor of this catalytic
function, i.e., SAFit2, which produced similar results to
those found in FKBP51s silencing14.
The present study confirms that PD-L1 exerts impor-
tant tumor-intrinsic properties in GBM. In particular, we
show that PD-L1 sustains cell survival, resistance and
stemness capability. PD-L1 expression was highest in
GBM cancer-initiating cells, due to a post-transcriptional
regulatory effect involving FKBP51s. Targeting of
FKBP51s by gene silencing or via the selective inhibitor
SAFit2, downmodulated PD-L1 expression and inhibited
spheroid formation when GBM cancer-initiating cells
were cultured under non-adherent conditions. In an
orthotopic GBM mouse model, SAFit2 showed an anti-
tumor effect, as assessed by reductions in tumor volumes,
caspase activation and attenuated expression levels of PD-
L1 and the mesenchymal marker vimentin.
Results
PD-L1 promotes apoptosis resistance
We investigated the effect of PD-L1 silencing on GBM
cell survival. To this end, we used two human GBM cell
lines previously found to highly express PD-L1 and
FKBP51s, namely, D54MG and U251MG cells14. For PD-
L1 downmodulation, cells were treated with specific siR-
NAs targeting PD-L1 or its co-chaperone FKBP51s.
Twenty-four hours after transfection, some of the cells
were harvested for lysate preparation. After a further 24 h,
the remaining cells were collected for cell-death mea-
surements via PI incorporation. Figure 1a shows a western
blot assay of lysates obtained from human D54MG cells
treated with three different FKBP51s siRNAs and a spe-
cific PD-L1 siRNA (siPD-L1). Two of the three siRNAs
were designed on the 3′-UTR (siFKBP51sUTR1 and
siFKBP51sUTR2) and another (siFKBP51) on the coding
region. The PD-L1 signals at ≈50 kDa are those of mature
(glycosylated) forms and those under 37 kDa correspond
to the naive protein14 (Fig. 1a). SiFKBP51s and
siFKBP51sUTR1 appeared to downmodulate FKBP51s
more efficiently than siFKBP51sUTR2. Expression of PD-
L1 was also decreased by siFKBP51s and siFKBP51sUTR1,
in comparison to the control cells (NSRNA or none). The
procaspase-7 level was decreased by the same siRNAs,
with a cleaved fragment at ≈20 kDa also observable,
consistent with apoptosis activation (Fig. 1a). Measure-
ment of hypodiploid cells confirmed that PD-L1 down-
modulation, like FKBP51s silencing, produced cell death
(Fig. 1a). The effect of different siRNAs on both FKBP51s
and PD-L1, was also assessed in U251MG, as shown in the
Supplementary Information (Fig. S1). Since siPD-L1 and
siFKBP51s appeared to be the most effective for target
downmodulation, these siRNAs were used in subsequent
experiments. Human U251MG cells showed similar
results to those obtained with D54MG cells (Fig. 1b). Both
PD-L1 and FKBP51s silencing decreased PD-L1
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expression levels, but only FKBP51s siRNA decreased the
FKBP51s expression level. Activation of caspase-3 was
registered in U251MG cells using flow cytometry (Sup-
plementary Information, Fig. S2). We, then, investigated
the effect of PD-L1 silencing on etoposide-induced cell
death. Silencing of PD-L1 appeared to exert a cytotoxic
effect similar to that of etoposide. However, combination
of the two factors appeared to further increase cell death,
in comparison with the single treatment. This result
suggested that reduced levels of PD-L1 could act in
concert with the chemotherapeutic compound to enhance
its cytotoxicity (Fig. 1c). Using flow cytometry, we found
that both cell lines, when cultured with etoposide for 6 h,
had increased levels of PD-L1, compared to the same
Fig. 1 PD-L1 regulates glioma cell apoptosis. a Analysis by western blot assay of PD-L1 and FKBP51s expression levels in D54MG cells, silenced for
FKBP51s, using different siRNAs (siFKBP51sUTR1, siFKBP51sUTR2, and siFKBP51s) or PD-L1. The blot also shows caspase-7 levels recognized in its inactive
(procaspase) and active forms. On the bottom of the panel, means and standard deviations of cell-death values of D54MG cells silenced for FKBP51s
and PD-L1, are shown. Columns indicate the percentage of hypodiploid cells (N= 4). b Western blot assay of PD-L1 and FKBP51s levels in U251MG
cells silenced for FKBP51s and PD-L1. On the bottom of the panel, means and standard deviations of cell-death values of U251MG cells silenced for
FKBP51s and PD-L1, are shown. Columns indicate the percentage of hypodiploid cells (N= 4). c Graphical representation of means and standard
deviations of cell-death values in PD-L1-depleted D54MG and U251MG cells. Twenty-four hours after transfection with PD-L1 siRNA, cells were treated
with etoposide. They were then harvested after a further 24 h and analyzed for PI incorporation via flow cytometry. Columns indicate the percentage
of hypodiploid cells (N= 3). d Flow-cytometric histograms of PD-L1 expression in D54MG and U251MG cells, cultured for 6 h with etoposide. On the
right, a graphical representation is given of values (mean and standard deviation) from three different experiments. e Western blot assay of PD-L1
levels in GBM cells cultured with etoposide. f Measurement by qPCR of FKBP51s transcript level in cells treated or not treated with etoposide, for 6 h
(N= 4). g Western blot assay of exogenous PD-L1 levels in D54MG and U251MG cells cultured in the absence or the presence of etoposide.
h Graphical representation of means and standard deviations of cell-death values in PD-L1 D54MG and U251MG glioma cells. Twenty-four hours after
transfection with EV or PD-L1-GFP, cells were treated with etoposide. They were then harvested after a further 24 h and analyzed for PI incorporation
via flow cytometry. Columns indicate the percentage of hypodiploid cells. Each experiment was performed at least three times and in triplicate
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untreated cells (Fig. 1d). As expected, western blot ana-
lysis confirmed the increase in the mature PD-L1 signals
at 50 kDa (Fig. 1e) and showed an increased expression of
FKBP51s in etoposide-treated cells. These results sug-
gested that etoposide induced FKBP5 mRNA splicing,
which was confirmed at the transcription level (Fig. 1f).
Ectopic expression of PD-L1 (Fig. 1g), significantly
reduced etoposide-induced cell death (Fig. 1h). Taken
together, these results suggest that PD-L1 is a resistance
factor for GBM cells. Further confirmation of the PD-L1
pro-survival effect was obtained with the other two GBM
cell lines, namely, U87MG and SF767 (see Supplementary
Information, Figs. S3 and S4 respectively). Interestingly, in
SF767 cells, which show deficient PD-L1 levels14, PD-L1
silencing did not produce an apoptosis-enhancing effect,
whereas PD-L1 ectopic expression reduced etoposide
cytotoxicity (Supplementary Information, Fig. S4).
FKBP51s promotes apoptosis resistance
Since FKBP51s deprivation reduces PD-L1 expression14,
we investigated whether FKBP51s affected GBM cell
death using RNA silencing. The effect of protein down-
expression was assessed using western blot analysis (Fig. 2a).
Cell death was assessed in the absence or the presence of
etoposide, via PI incorporation. Figure 2a shows repre-
sentative flow-cytometric histograms of hypodiploid
events and a graphic representation of the means and
standard deviations of cell-death values obtained in three
independent experiments, each performed in triplicate.
FKBP51s silencing in D54MG cells produced 20.0 ± 4.0%
cell death, while treatment of cells with a non-silencing
oligo (NSRNA) produced only 2.3 ± 0.5% cell death (p=
0.01) (Fig. 2a). Similarly, in etoposide-treated cells,
FKBP51s siRNA and NSRNA produced 28.0 ± 4.0% and
20.0 ± 0.1% cell death respectively (p= 0.01) (Fig. 2a).
FKBP51s-silenced U251MG produced an average of
14.3 ± 4.0% cell death, while NSRNA produced only 3.3 ±
0.5% cell death (p= 0.03) (Fig. 2a). In etoposide cultures,
FKBP51s siRNA and NSRNA produced 55.0 ± 4.1% and
46.7 ± 1.1% cell death respectively (Fig. 2a) (p= 0.05). To
confirm the role of FKBP51s in the resistance of GBM
cells, we overexpressed FKBP51s and analyzed cell death
using EV cells for comparison. In line with the FKBP51s
knockdown sensitizing effect, we registered a significant
decrease in etoposide-induced cell death in D54MG and
U251MG cells transfected with FKBP51s vector, com-
pared with EV cells (p= 0.03 and p= 0.004 for D54MG
and U251MG, respectively) (Fig. 2b). To investigate
whether PD-L1 requires FKBP51s to counteract
chemotherapy-induced cell death, we overexpressed PD-
L1 under conditions of FKBP51s depletion. To this end,
we co-transfected PD-L1 and FKBP51s siRNA or NSRNA,
in D54MG and U251MG cells (Fig. 2c), and measured cell
death in etoposide cultures (Fig. 2d). The silencing of
FKBP51s hampered the pro-survival effect of ectopic PD-
L1 (Fig. 2d). The cell-death modulatory effect of FKBP51s
was also assessed in U87MG cell lines (Supplementary
Information, Fig. S5), as well as using SAFit2 (Supple-
mentary Information, Fig. S6).
PD-L1 expression increases with glioma aggressiveness
and affects spheroid formation in culture
The role of PD-L1 in the apoptosis resistance of GBM
cells, together with its previous involvement in EMT10,
supports the concept that this immune checkpoint is a
hallmark of GBM malignancy. To address whether PD-L1
expression increased with the aggressiveness of GBM
cells, we used two GBM cell lines previously established
by Kroonen et al.19 from the tumor mass (TM-GBM) and
the subventricular zone (SVZ-GBM) of an orthotopic
GBM model. TM-GBM and SVZ-GBM cell lines, char-
acterized by an increasing level of aggressiveness from
TM to SVZ, were derived from the human U87MG cell
line. SVZ-GBM cells are particularly rich in GBM cancer
stem cells and have a high tumorigenic potential, as
assessed by mouse reinjection19 or by their capacity to
grow in spheres when cultured under non-adherent
conditions20. We confirmed the high tumorigenicity of
SVZ-GBM cells showing increased levels of p-Akt, along
with its substrate p-S6K1 (Fig. 3a) and the stemness
marker CD133 (Fig. 3b), in comparison to TM-GBM cells.
SVZ-GBM also showed increased PD-L1 expression in
contrast to TM-GBM cells, as assessed by western blot
analysis (Fig. 3b) and flow cytometry (Fig. 3c). Surpris-
ingly, PD-L1 mRNA levels appeared to be higher in the
TM-GBM cells than in the SVZ-GBM cells (Fig. 3d). In
line with Goffart et al.20, we found that SVZ-GBM cells
have an increased capacity to form spheroids in com-
parison with TM-GBM cells (Fig. 3e). As expected,
spheroids (+) expressed Sox-2 levels remarkably higher
than those in the corresponding adherent cells (-)
(Fig. 3e). Expression of PD-L1 resulted especially in an
increase in spheroids formed by TM-GBM cells, in
comparison with attached TM-GBM cells. Although only
a slight increase in PD-L1 expression was observed in
SVZ-GBM cells growing in spheres (Fig. 3f), the finding
that PD-L1 silencing impaired the capacity to form
spheroids in both TM- and SVZ-GBM cells (Fig. 3g)
highlighted the importance of PD-L1 in spheroid forma-
tion. Taken together, our results indicate that PD-L1 is a
necessary but not a sufficient condition for allowing the
GBM cells to grow in spheres.
Targeting of FKBP51s downregulates PD-L1 and hampers
GBM malignancy
Since the increased expression of PD-L1 in SVZ-GBM
cells, in comparison to TM-GBM cells, appeared to be
related to a post-transcriptional mechanism, we investigated
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the effect of FKBP51s silencing on the modulation of PD-L1
levels in both TM-GBM and SVZ-GBM cells. As shown in
the western blot in Fig. 4a, the silencing of FKBP51s
downmodulated PD-L1 levels in both cell lines. This result
was confirmed using flow cytometry (Fig. 4b). FKBP51s
downmodulation impaired spheroid formation in both TM-
GBM and SVZ-GBM cells (Fig. 4c). Interestingly, SVZ-
GBM appeared to be more sensitive than TM-GBM to the
targeting of FKBP51s, according to the PD-L1 down-
expression, which was more powerful in SVZ-GBM than in
TM-GBM cells (Fig. 4b). FKBP51s silencing counteracted
the effect of ectopic PD-L1-GFP in promoting spheroid
formation (Fig. 4d, e). A western blot validated the impact
of FKBP51s silencing on protein levels (Fig. 4f). We then
investigated the effect of SAFit2 on PD-L1 expression and
spheroid formation in TM-GBM and SVZ-GBM cells. PD-
L1 expression, as assessed by flow cytometry, showed a
significant decrease on the plasma membrane in SAFit2
cultures (Fig. 5a). Like FKBP51s siRNA, SAFit2 impaired
spheroid formation in both TM-GBM and SVZ-GBM cells
(Fig. 5b). To address whether SAFit2 could affect tumor
growth, we assessed Ki67 expression and cell counts in TM-
Fig. 2 FKBP51s regulates glioma cell death. a Western blot assay of FKBP51s levels in D54MG and in U251MG silenced for FKBP51s. Cells were
treated with FKBP51s siRNA or NSRNA for 24 h. Then, some of the cells were harvested for lysate preparation and some cells were treated with
etoposide. After a further 24 h, cell death was measured. Representative flow-cytometric histograms of PI incorporation are shown along with
graphical representations of means and standard deviations of cell-death values (N= 3). b Western blot assays of exogenous FKBP51s levels and
graphical representations of means and standard deviations of cell-death values in D54MG and U251MG cells transfected with FKBP51s with EV- or
FKBP51s-carrying plasmids (N= 3). Cells were treated with etoposide at 24 h from transfection. After a further 24 h, cell death was measured by flow
cytometry (N= 3). c Western blot assays of the exogenous PD-L1-GFP level in D54MG and U251MG cells, silenced or not silenced for FKBP51s.
Silencing of FKBP51s produced a decrease in PD-L1-GFP level in both cell lines. d D54MG and U251MG cells transfected with EV, PD-L1-GFP+NSRNA
and PD-L1-GFP+ FKBP51s siRNA, were treated with etoposide. After 24 h, cell death was measured using flow cytometry. FKBP51s depletion reduced
the antiapoptotic effect of exogenous PD-L1. Each experiment was performed at least three times and in triplicate
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GBM and SVZ-GBM cell cultures (Fig. 5c, d). On SAFit2
treatment, both cell lines showed a significant decrease in
Ki67 expression (Fig. 5c) and cell counts (Fig. 5d). To
address the in vivo effect of SAFit2, U87MG cells (carrying
GFP and the luciferase reporter gene) were injected into the
right striatum of 32 nude mouse brains. Two weeks later, 16
mice were treated daily with SAFit2, while 16 mice were
treated intraperitoneally with a vehicle designed to pass
through the brain-blood barrier, via intraperitoneal injec-
tion. After 2 weeks of treatment (corresponding to 4 weeks
from cell xenotransplantation) the mice were sacrificed, and
the brains obtained. A reduced tumor mass was calculated
in mice treated with SAFit2 compared to tumors from mice
treated with the vehicle (Fig. 6a). The result was confirmed
by a reduced luminescence intensity recorded in the living
mice before the sacrifice (Fig. 6b). The reduced tumor
growth was accompanied by the presence of active caspase-
3 in xenografts from the SAFit2-treated mice (Fig. 6c). In
accordance with in vitro findings, SAFit2 reduced tumor
PD-L1 expression (Fig. 6d). Finally, in-brain slices, the
percentage of tumor cells found to be positive for the
expression of the mesenchymal marker vimentin, was still
reduced in mice treated with SAFit2 (Supplementary
Information, Fig. S6).
Discussion
A growing body of literature supports the concept that
PD-L1 has intrinsic pro-tumoral aspects that are inde-
pendent of its immunoinhibitory functions6. Moreover,
several recent studies report that expression levels of PD-
L1 positively correlate with glioma grades. More precisely,
in GBM, these levels are much higher than in grade II and
grade III gliomas6.
In this paper, consistent with the finding of Azuma
et al.8 that PD-L1 is a ubiquitous antiapoptotic receptor,
we show that PD-L1 is an essential element in GBM
resistance to cell death. A previous paper also reported
that PD-L1 overexpression, as a result of the low miR-34a
Fig. 3 PD-L1 sustains GBM capacity to form spheroids. a Immunoblot of p-Akt and p-S6K1 in TM-GBM and SVZ-GBM cells. Levels of phospho-
enzymes were higher in SVZ-GBM cells than in TM-GBM cells. b Expression of PD-L1 and CD133 in TM-GBM and SVZ-GBM cells. Levels of both
proteins were higher in SVZ-GBM cells than in TM-GBM cells. c Flow cytometry measurements of PD-L1 expression in TM-GBM and SVZ-GBM cells.
Graph columns represent mean fluorescence intensities with related p-values (N= 3). A representative histogram is shown in overlay. d RT-qPCR
results for mRNA levels of PD-L1 in TM-GBM and SVZ-GBM cells. Graph columns represent normalized quantification relative to TM-GBM cells (N= 3).
e Representative images of formed spheroids taken using an optical microscope and spheroid counts in TM-GBM and SVZ-GBM cultures (scale bar
represents 100 μm). Graph columns represent spheroid numbers relative to TM-GBM cells (N= 3). A western blot of Sox-2 levels shows increased
levels of the stemness marker in the spheroids (+), in comparison with adherent cells (−). f Quantification using flow cytometry of PD-L1 levels, in
TM-GBM-formed spheroids and SVZ-GBM-formed spheroids. Graph columns represent MFI (N= 3). g Spheroid formation assay with TM-GBM and
SVZ-GBM cells silenced or not silenced for PD-L1. Graph columns represent the relative spheroid numbers after a 4-day culture. NSRNA-treated cells
were used as the reference sample. Each experiment was performed at least three times and in triplicate
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level in U87 glioma cells, induced paclitaxel resistance21.
In the present paper, we confirm the resistance effect of
PD-L1 in four different glioma cell lines, namely, U87MG,
D54MG, U251MG and SF767. Moreover, in accordance
with Zheng et al.9, who demonstrated a role for PD-L1 in
sustaining the self-renewal capability of malignant
melanoma-initiating cells, we show that PD-L1 expression
is increased in GBM cancer-initiating cells and has a
supporting role in spheroid formation. Finally, in accor-
dance with Qiu et al.10, who demonstrated the promoting
role of PD-L1 in GBM-cell migration, we found increased
expression of PD-L1 in GBM cells that had migrated to
the subventricular zone of the brain, compared with PD-
L1 expression in the nigrostriatal tumor mass. When the
levels of PD-L1 were downmodulated by FKBP51s silen-
cing, GBM-cell sensitivity to both spontaneous and
chemotherapy-induced death was increased. Moreover,
when the levels of PD-L1 were upregulated by an ectopic
expression, a pro-survival effect on GBM cells was
observed. This outcome was counteracted by FKBP51s
silencing, which is consistent with the essential role for
this co-chaperone in PD-L1 expression14. FKBP51s
appeared to significantly affect the spheroid formation
ability of GBM cancer-initiating cells, along with PD-L1.
Collectively, these findings, in addition to supporting the
pro-oncogenic role of PD-L1 in glioma, open up the
possibility of targeting PD-L1 by acting on its co-
chaperone FKBP51s. SAfit2 is, so far, the most well-
characterized FKBP51 ligand available22. After 2 weeks of
intraperitoneal treatment with SAFit2, assessment of
GFP+ luc+ tumor volumes in-brain slices showed a
significant decrease in SAFit2-treated mice, in compar-
ison with vehicle-treated control mice. Consistent with
this finding, reduced luminescence intensity was regis-
tered in SAFit2-treated tumors in living mice before
sacrifice. The presence of active caspase-3 in tumor
xenografts from SAFit2-treated animals suggested that
the reduction in tumor volumes can be ascribed, at least
in part, to apoptosis induction. A decreased percentage of
tumor cells expressing PD-L1 and vimentin, according to
histological examinations, suggested that in treated mice
the tumor had a reduced aggressiveness.
Fig. 4 FKBP51s regulates PD-L1 expression and spheroid formation in TM-GBM and SVZ-GBM cells. a Immunoblot of PD-L1 and FKBP51s
levels in cells silenced for FKBP51s. Canonical FKBP51 confirmed the specificity of the silencing. b Flow cytometry analysis of PD-L1 expression in cells,
silenced or not silenced for FKBP51s. Graph columns represent MFI using non-silenced cells as the reference sample (N= 3). c Spheroid assay with
cells from TM-GBM and SVZ-GBM cells, silenced or not silenced for FKBP51s. Representative images of formed spheroids are shown. Graph columns
represent the relative spheroid numbers, after a 4-day culture, using NSRNA-treated cells as the reference sample (N= 3). d Spheroid assay with
TM-GBM cells and SVZ-GBM cells transfected with EV, PD-L1-GFP+NSRNA, and PD-L1-GFP+ FKBP51s siRNA. FKBP51s depletion reduced the spheroid
formation stimulated by exogenous PD-L1 (scale bar represents 250μm) (N= 3). e Fluorescent microscopy visualization of ectopic PD-L1-GFP in the
spheroid assay (scale bar represents 50 μm). FKBP51s depletion reduced spheroid numbers and the extent of fluorescence. f Western blot assay of
FKBP51s levels in FKBP51s-silenced spheroids. Each experiment was performed at least three times and in triplicate
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In conclusion, in line with a previous study demon-
strating that in vivo knockdown of PD-L1 in nude mice
completely abolished GBM xenograft formation10, our
finding shows that manipulation of PD-L1, through che-
mical inhibition of its co-chaperone FKBP51s, activates
apoptosis and mitigates the aggressive features of GBM
xenografts in nude mice. Our study contributes some
information to the emerging concept that there is a strict
interplay between cancer immunoediting and resistance
and suggests that SAFit2 may be a beneficial neoadjuvant
strategy for the management of this tumor.
Methods and materials
Cell culture and transfection
Human glioma cell lines D54MG, U251MG, SF767MG
were obtained and cultured as described14. U87MG from
American Type Culture Collection (ATCC) were cultured
in Dulbecco’s Modified Eagle Medium (DMEM) containing
10% FBS, 200mM glutamine, and 100U/mL
penicillin–streptomycin. TM-GBM cells and SVZ-GBM
cells were U87MG cells obtained by microdissection of
xenografted mice brain19, from, respectively, the tumor
mass and the subventricular zone, and seeded in cultures19.
For FKBP51s and PD-L1 knockin and knockdown, cells
were transfected using the K2 Transfection System (Bion-
tex, Munich, Germany), as previously described14 and in
accordance with the manufacturer’s recommendations. For
overexpressing FKBP51s and PD-L1 a True-ORF-Myc-
DDK-tagged and a True-ORF-GFP-tagged expression vec-
tors were used (OriGene Technologies, Rockville, MD,
USA), which carried the complementary DNA (cDNA) of
the human FKBP5 transcript variant 4 and CD274,
respectively. Control cells were transfected with the related
empty vector (EV). FKBP51s silencing was performed using
short-interfering oligoribonucleotides. The siFKBP51 was a
mix of two siRNAs designed on the coding region;
siFKBP51sUTR1and FKBP51sUTR2 were designed on 3′-
UTR14. The non-silencing RNA (NSRNA) and PD-L1
siRNA were from Qiagen (siPD-L1) (Valencia, CA, USA) or
Novus Biologicals (siPD-L1.2) (Littleton, CO). U87MG cells
used for xenograft implantation were previously transduced
with lentiviral vectors allowing the dual expression of eGFP
and luciferase as previously described20. In experiments
with etoposide, the drug was added 24 h after transfection at
a concentration of 20 μM. For experiments with SAFit222,
which was provided by Prof. Felix Hausch laboratory, a
stock solution (60 μM in DMSO) was used at 1:1000 dilu-
tion in DMEM-F12 media; for control cells, DMSO has
diluted accordingly.
Western blot
Whole-cell lysates were homogenized in modified RIPA
buffer14 and assayed by immunoblot as previously
described14. The primary antibodies against FKBP51
(rabbit polyclonal; Novus Biological), FKBP51s13 and
CD274/PD-L1 (rabbit polyclonal; Novus Biological) were
Fig. 5 SAFit2 decreases PD-L1 expression and spheroid formation and impairs in vitro growth of TM-GBM and SVZ-GBM cells. a Cytometry
analysis of PD-L1 expression in cells treated with SAFit2 for 12 h. Graph columns represent mean fluorescence intensities using cells with Dimethyl
sulfoxide (DMSO) as the reference sample (N= 3). b Spheroid assay with cells treated with SAFit2 or the vehicle. Representative pictures of formed
spheroids are shown along graph columns for the relative spheroid number measured after a 4-day culture. DMSO-treated cells were used as the
reference sample (N= 3). c Ki67 expression measured by immunofluorescence in cells treated with SAFit2 or the vehicle (scale bar represents 25 μm).
Graph columns represent the percentage of Ki67-positive cells, relative to the control (N= 6). d Kinetics of counts of TM-GBM and SVZ-GBM cells
treated with SAFit2 or the vehicle. SAFit2 significantly reduced cell counts (N= 4)
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used diluted 1:2500. CD133 (rabbit polyclonal; Abcam;
Cambridge, UK) was used diluted 1:1000. A further
antibody Pdcd-1L1 (rabbit polyclonal, Santa Cruz Bio-
technology; Santa Cruz, CA, USA) was used for PD-L1
detection at the 1:1000 dilution. Antibody against M2-
Flag, caspase-7 and γ-Tubulin (mouse monoclonal;
Sigma-Aldrich, St. Louis, MO, USA) were used diluted
1:5000. Anti β-Actin-Peroxidase (mouse monoclonal;
Sigma-Adrich) was used diluted 1:10000. Anti-phospho-
Akt (Ser473), Akt1/2/3, phosphor-S6 kinase, G3PDH
and Sox-2 (rabbit monoclonal; Cell Signaling, Danvers,
MA, USA) were used diluted 1:1000. Anti-p70S6
kinase (rabbit polyclonal; Santa Cruz) was used
diluted 1:500.
Fig. 6 SAFit2 impairs GBM growth in vivo. a Graphic representation of tumor volumes formed in 16 mice treated daily with vehicle and 16 mice
treated with SAFit2. b Luciferase assay, performed on mice treated or not treated with SAFit2, 2 weeks after in-brain injection with GFP+ luc+ U87MG
cells. Three mice from each group are shown before starting the treatment and after 10 days (left). Graph columns represent mean values of signal
intensities from the two groups, before and after treatment (right) (N= 16). c Expression of active caspase-3 by immunofluorescence on brain slices
(scale bar represents 50 μm). Box plots represent the values of GFP+ cleaved Casp3+ cells measured using ImageJ software, from seven mice treated
with vehicle and seven mice treated with SAFit2. d Expression of PD-L1 determined by immunofluorescence on brain slices (scale bar represents
50 μm). Box plots represent the values of GFP+ PD-L1+ cells measured using ImageJ software, from nine mice treated with vehicle and nine mice
treated with SAFit2
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Flow cytometry
Expression of PD-L1 was assessed using anti-B7H1-
phycoerythrin (PE) (R&D Systems, Minneapolis, MN,
USA) at a concentration of 0.05 μg/ml. A PE-conjugated
control Ig isotype was used to assess non-specific binding.
Briefly, cells were harvested and incubated with the
antibodies mentioned above for 30min in the dark at 4 °C,
washed and then analyzed with a BD Accuri™ C6 Cyt-
ometer (BD Biosciences, New Jersey, USA). Cleaved
caspase-3 immunostaining was performed as previously
described23. Apoptosis was assessed by two methods:
propidium iodide (PI) incorporation to analyze the DNA
content in permeabilized cells24, and the annexin V-
binding assay in double staining with PI, according to
Vermes et al.25. Cells were analyzed with a BD Accuri™ C6
Cytometer (BD, Becton Dickinson).
Microscopy
Before the immunostaining, cells were seeded for 3 h on
coverslips coated with polyornithine (0.1 mg/ml), then,
after washing with PBS the cells were fixed in 4% paraf-
ormaldehyde (PFA) for 15min. Brain coronal sections or
cells on coverslips were permeabilized and unspecific
binding sites were blocked for an hour at room tem-
perature using a 10% donkey serum and 0.2% Triton X-
100 PBS solution. Tissue sections or coverslipped cells
were then incubated overnight at 4 °C with primary
antibodies diluted in PBS containing 0.1% of donkey
serum and 0.1% of Triton X-100, followed by tetra-
methylrhodamine (TRITC)-, fluorescein isothiocyanate
(FITC)-conjugated, or cyanine 5 (Cy5) secondary anti-
bodies (Jackson Immunoresearch Laboratories; Cam-
bridge, UK) diluted 1:500. Anti Ki-67 (BD Biosciences,
Becton Dickinson) was used diluted 1:500. Anti-Vimentin
(rabbit monoclonal IgG, Cell Signaling, Danvers, MA,
USA) was used diluted 1:400. Anti-PD-L1 (mouse
monoclonal, Abcam; Cambridge, UK) was used diluted
1:200. Anti-Active Caspase-3 (Affinity-purified rabbit IgG,
Promega, Madison, Wisconsin, USA) was diluted 1:250.
Anti-GFP (chicken polyclonal, Abcam; Cambridge, UK)
was used diluted 1:500. Counterstaining with DAPI
(D9542, Sigma-Aldrich, St. Louis, MO, USA) was per-
formed and slides coverslipped with Fluoromount-G
(00–4958–02, Invitrogen, Carlsbad, CA, USA). Images
were acquired with OLYMPUS FV1000 confocal micro-
scopy. For PD-L1 and active caspase-3 expression, fluor-
escence intensity was quantified according to “corrected
total cryosection fluorescence” (CTCF)26. Quantification
of vimentin expression in-brain slices was performed as
followed: mean fluorescence intensity (MFI) was calcu-
lated for each GFP+ cell stained with anti-vimentin along
with GFP+ cell stained with control antibody. Positivity
was assigned when vimentin MFI was at least four-fold
higher than control MFI. When required, the brightness,
contrast, and color balance of the images were adjusted in
Photoshop CS2 (Adobe Systems, San Jose, California,
USA). This adjustment was applied to every pixel in
each image.
Quantitative PCR (qPCR)
Total RNA was extracted from cells by Trizol (Invitro-
gen, Carlsbad, CA, USA). Each RNA was used for cDNA
synthesis with iScript Reverse Transcription (Bio-Rad,
CA, USA). Relative gene expression was quantified by
qPCR with 2–ΔCt comparative method27, using the
SsoAdvancedTM SYBR Green Supermix (Bio-Rad) and
specific qPCR primers. Amplification of FKBP51s was
performed as previously described13. Oligo sequences
used for PD-L1 mRNA quantitation along with co-










TM- and SVZ-GBM cells were cultured in DMEM/F12
serum-free medium containing B-27-Supplement without
vitamin A (Life Technologies; Carlsbad, CA, USA) and
supplemented with recombinant epidermal growth factor
and fibroblast growth factor 2 (EGF, 20 ng/mL and FGF-2,
10 ng/mL; Preprotech, London, UK). After 4 days in cul-
ture, the number of spheroids was counted using an
optical microscope.
Proliferation assay
TM- and SVZ-GBM cells were daily treated with 60 nM
SAFit2 or opportunely diluted DMSO. Every 2 days, cells
were harvested, and cell number was estimated by the
Countess II Automated Cell Counter (Life Technologies).
After a 4-day treatment, cells were seeded on a coverslip
and processed for Ki67 immunostaining as previously
described.
Animal studies
P40 female immune-deficient mice (Crl:NU-Foxn1nu)
were obtained from Charles River Laboratories (Charles
River Laboratories®, Wilmington, UK) and handled
according to the Animal Ethical Committee of the Uni-
versity of Liège. All animals were cared for in accordance
with the Declaration of Helsinki and the guidelines of the
Belgium Ministry of Agriculture, in agreement with
the European Commission Laboratory Animal Care and
Use Regulation (86/609/CEE, CE of J nL358, 18 December
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1986). For intracranial transplantation, mice were anes-
thetized with an intraperitoneal injection of ketamine
(50 mg/mL, Pfizer, Bruxelles, Belgium) and xylazine
(Sedativum 2%, Bayer, Bruxelles, Belgium) solution (V/V).
The cranium was exposed and a small hole was drilled
2.5 mm lateral and 0.5 mm anterior to the bregma with a
size 34 Dremel Inverted Cone Burr. Mice were positioned
in a stereotactic frame and 50000 GFP+ luc+U87MG
cells in 2 µl PBS were injected into the right striatum
through a 27-gauge needle over 1 min at 3 mm below the
dura mater. The incision was closed with 3M Vetbond
Tissue Adhesive (Fisher Scientific, Hampton, NH, USA).
For mice treatment, with SAFit2, this was performed as
previously described22. Before obtaining brains, mice were
anaesthetized with an injection of Nembutal (Pento-
barbital 60 mg/mL; Ceva Sante Animal, Libourne, France)
followed by an intracardiac perfusion with a NaCl 0.9%
solution (VWR International, Radnor, PA, USA) plus 4%
PFA at 4 °C (4,3 g/L NaOH, 40 g/L PFA, 18.8 g/L
NaH2PO4). Then after, brains were collected, postfixed in
4% PFA and cryoprotected overnight in a 20% PBS/
sucrose solution. Brains were frozen at −20 °C in a 2-
methylbutane solution (Sigma-Adrich) and cut into 14 μm
thick coronal sections using a cryostat. The tumor volume
was calculated on GFP+ areas using ImageJ and, accord-
ing to Kim et al.28, the formula (Volume= 0.5 × length ×
width × height). For bioluminescence imaging: immuno-
deficient nude mice bearing intracranial xenografts were
injected intraperitoneally with D-luciferin (150 mg/kg,
Sigma-Adrich). After anesthesia using 2.5% isoflurane,
mice were imaged with a charge-coupled device camera-
based bioluminescence imaging system (IVIS 50, Xeno-
gen; exposure time 1–30 s, binning 8, field of view 12, f/
stop 1, open filter).
Statistical analysis
Student’s t-test was used to analyze differences between
means of values. A p-value of ≤0.05 was considered sta-
tistically significant.
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